Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016923
Chunk: 2

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 2
---
 the prospectus that forms a part of this Post-Effective Amendment. Pursuant to Rule 416 under the Securities Act, there are also being registered such securities that may be issued because of events such as recapitalizations, stock dividends, stock splits and reverse stock splits, and similar transactions.

No additional securities are being registered under this Post-Effective Amendment. All applicable registration fees were paid at the time of the original filing of the August 2022 Registration Statement. Accordingly, we hereby amend the August 2022 Registration Statement, as amended and supplemented through the date hereof, by filing this Amendment,

The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

<div align='center'>bioAffinity Technologies, Inc.

4,360,829 Shares of Common Stock</div>

This prospectus relates to the issuance by bioAffinity Technologies, Inc. (the “ Company”) of 4,305,713 shares of common stock, par value $0.007 per share (the “Common Stock”), upon exercise of outstanding warrants issued to investors in our initial public offering and 55,116 shares of Common Stock underlying Placement Agent Warrants and Representative’s Warrants.

On September 6, 2022 we completed our initial public offering (the “ Offering”) of 1,285,325 units (each, a “ Unit,” collectively, the “ Units”). Each Unit consisted of one share of our Common Stock, one tradeable warrant (each, a “ Tradeable Warrant,” collectively, the “ Tradeable Warrants”) to purchase one share of Common Stock at an exercise price of $7.35 per share, which has since been adjusted to $3.0625, and one non-tradeable warrant (each, a “ Non-Tradeable Warrant,” collectively, the “ Non-Tradeable Warrants”; together with the Tradeable Warrants, each, a “ Warrant,” collectively, the “ Warrants”) to purchase one share of Common Stock at an exercise price of $7.656 per share which has since been adjusted to $3.0625 pursuant to an anti-dilution provision contained in the Warrants. The number of shares of Common Stock issuable upon exercise of the Warrants was adjusted pursuant